Symvivo has enrolled and dosed the first healthy volunteer in a Phase I trial in Australia to evaluate its oral Covid-19 vaccine candidate, bacTRL-Spike.

Each oral dose of the vaccine candidate has bacterial medium with either one billion, three billion or ten billion colony-forming units of live Bifidobacterium longum.

BacTRL-Spike is designed to deliver plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2.

The Phase I trial, ‘Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 (NCT04334980)’, will analyse the safety, tolerability and preliminary evidence of immunogenicity to SARS CoV-2 elicited by the vaccine among healthy adults.

It is being conducted in collaboration with Nucleus Network in Brisbane, Australia for 18 months and plans to enrol 12 healthy participants.

Each participant will remain in the trial for 12-13 months. This will include a screening phase of up to 28 days, intervention phase of one day and follow-up phase of 12 months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary investigator of the trial is Nucleus Network infectious diseases physician and microbiologist Paul Griffin.

Preliminary data from the trial is anticipated early next year.

Setting itself apart from the traditional vaccines that are delivered by intramuscular injection, bacTRL-Spike is taken orally and helps people to self-administer with no trained medical professional required to carry out the process.

Symvivo chief medical officer Eric Sievers said: “We are exceptionally pleased to commence dosing of our oral DNA vaccine for Covid-19 as we continue scale-up and manufacturing activities for future clinical development.

“The rapidly advancing pandemic mandates innovative scientific approaches and we believe a safe, protective oral vaccine could transform the landscape of traditional vaccination approaches, eliminating the need for syringes, needles, and trained vaccinators.”